FEP CHR PoC
Research payments
$1,593,990
Through program year 2023, $1,593,990 in research payments was reported against FEP CHR PoC, across 139 payments, paid by Boehringer Ingelheim Pharmaceuticals, Inc..
- Paid by
- Boehringer Ingelheim Pharmaceuticals, Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
5 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2023 | Research | $3,040 | 1 |
| 2022 | Research | $36,322 | 5 |
| 2021 | Research | $200,249 | 26 |
| 2020 | Research | $635,904 | 51 |
| 2019 | Research | $718,476 | 56 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Stephan Taylor Ann Arbor, MI Named on 8 payments
- Joshua Kantrowitz New York, NY Named on 6 payments
- Steven Dubovsky Buffalo, NY Named on 6 payments
- David Brown Austin, TX Named on 5 payments
- Caleb Adler Cincinnati, OH Named on 5 payments
- Mary Knesevich Irving, TX Named on 4 payments
- Christian Kohler Philadelphia, PA Named on 4 payments
- Sarah Atkinson Rochester, NY Named on 4 payments
- Joseph McEvoy Augusta, GA Named on 4 payments
- Eric Achtyes Grand Rapids, MI Named on 4 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.